Esther Tahover

1.0k total citations
21 papers, 720 citations indexed

About

Esther Tahover is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Esther Tahover has authored 21 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Esther Tahover's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Nanoparticle-Based Drug Delivery (4 papers). Esther Tahover is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Nanoparticle-Based Drug Delivery (4 papers). Esther Tahover collaborates with scholars based in Israel, United States and Ireland. Esther Tahover's co-authors include Alberto Gabizón, Yogita P. Patil, Talia Golan, Joanne F. Chou, Richard Kinh Gian, David P. Kelsen, Maeve A. Lowery, Marinela Capanu, Kenneth H. Yu and Alice P. Chen and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Psychiatry and Advanced Drug Delivery Reviews.

In The Last Decade

Esther Tahover

19 papers receiving 711 citations

Peers

Countries citing papers authored by Esther Tahover

Since Specialization

Citations

This map shows the geographic impact of Esther Tahover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther Tahover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther Tahover more than expected).

Fields of papers citing papers by Esther Tahover

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther Tahover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther Tahover. The network helps show where Esther Tahover may publish in the future.

Co-authorship network of co-authors of Esther Tahover

This figure shows the co-authorship network connecting the top 25 collaborators of Esther Tahover. A scholar is included among the top collaborators of Esther Tahover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther Tahover. Esther Tahover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle East 2024 ·Frontiers in Oncology ·Suyog Jain, Shaheenah Dawood, (unknown), Dan Aderka, Esther Tahover, (unknown), Mark Temper, (unknown), (unknown), Steve Olsen, (unknown), (unknown), (unknown)	0
2	A universal cell‐free DNA approach for response prediction to preoperative chemoradiation in rectal cancer 2022 ·International Journal of Cancer ·Albert Grinshpun, (unknown), Daniel Neiman, Roni Lehmann‐Werman, Aviad Zick, Karen Meir, (unknown), Roy Z. Granit, (unknown), (unknown), (unknown), Eli Sapir, Myriam Maoz, Esther Tahover, Joshua Moss, Iddo Z. Ben‐Dov, Tamar Peretz, Ayala Hubert, Ruth Shemer, Yuval Dor	7
3	Anemia can predict the prognosis of colorectal cancer in the pre-operative stage: a retrospective analysis 2021 ·World Journal of Surgical Oncology ·(unknown), Dan M. Livovsky, Esther Tahover, Eran Goldin, Benjamin Koslowsky	22
4	Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside 2020 ·Advanced Drug Delivery Reviews ·Alberto Gabizón, Hilary Shmeeda, Esther Tahover, (unknown), Yogita P. Patil, Yasmine Amitay, Patricia Ohana, Eli Sapir, Samuel Zalipsky	35
5	Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients 2020 ·Investigational New Drugs ·Alberto Gabizón, Esther Tahover, Talia Golan, Ravit Geva, Ruth Perets, Yasmine Amitay, Hilary Shmeeda, Patricia Ohana	15
6	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation 2020 ·Journal of Clinical Oncology ·Eileen M. O’Reilly, Jonathan W. Lee, Mark M. Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A. Lowery, Joanne F. Chou, Vaibhav Sahai, Robin Brenner, Hedy L. Kindler, Kenneth H. Yu, Alice Zervoudakis, Shreya Vemuri, Zsofia K. Stadler, Richard Kinh Gian, Neesha C. Dhani, Alice P. Chen, David P. Kelsen	253
7	A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation. 2020 ·Journal of Clinical Oncology ·Eileen M. O’Reilly, Jonathan W. Lee, Mark M. Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A. Lowery, Joanne F. Chou, Vaibhav Sahai, Robin Brenner, Hedy L. Kindler, Kenneth H. Yu, Alice Zervoudakis, Shreya Vemuri, Zsofia K. Stadler, Richard Kinh Gian, Neesha C. Dhani, Alice P. Chen, David P. Kelsen	8
8	EUS-GUIDED, RFA ABLATION OF BENIGN AND MALIGNANT PANCREATIC NEOPLASMS AND EXTRA PANCREATIC METASTASIS IS FEASIBLE AND SAFE 2019 ·Endoscopy ·Alain Dancour, Misgav Rottenstreich, (unknown), Esther Tahover, Dov Wengrower, Eran Goldin, Talia Golan, (unknown)	0
9	An exceptional response to immunotherapy doublet in combined hepatocellular carcinoma-cholangiocarcinoma 2019 ·Annals of Oncology ·Esther Tahover	6
10	Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience 2018 ·Frontiers in Oncology ·Esther Tahover, Rachel Bar‐Shalom, Eli Sapir, Raphael Pfeffer, (unknown), (unknown), (unknown), Patricia Ohana, Benjamin W. Corn, Andrew Z. Wang, Alberto Gabizón	10
11	Impact of germline BRCA identification on subsequent breast cancer stage and therapy: Implications for routine screening. 2018 ·Journal of Clinical Oncology ·Tal Hadar, (unknown), (unknown), Sari Lieberman, Esther Tahover, Ora Rosengarten, Moshe Carmon, Oded Olsha, (unknown), Rachel Michaelson‐Cohen, Eliahu Golomb, Rachel Rabinovitch, Ephrat Levy‐Lahad	1
12	Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer 2017 ·Anti-Cancer Drugs ·Esther Tahover, Amiel Segal, Rut Isacson, Ora Rosengarten, Tal Grenader, (unknown), Nathan I. Cherny, Norman Heching, (unknown), Raphael Catane, Alberto Gabizón	38
13	A phase 1B study of pegylated liposomal mitomycin-C prodrug with or without capecitabine and bevacizumab in third line chemotherapy of colorectal cancer 2016 ·Annals of Oncology ·Alberto Gabizon, Tal Grenader, Esther Tahover, Hilary Shmeeda, Talia Golan, Raanan Berger, Ravit Geva, Ido Wolf, Ruth Perets, Yasmine Amitay, Patricia Ohana	2
14	MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing 2016 ·Anti-Cancer Drugs ·Esther Tahover, (unknown), Naama Bogot, David P. Kelsen, Alberto Gabizón	1
15	An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group 2014 ·Targeted Oncology ·Esther Tahover, Ayala Hubert, Mark Temper, Azzam Salah, Tamar Peretz, Tamar Hamburger, Beatrice Uziely	18
16	Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index 2014 ·Anti-Cancer Drugs ·Esther Tahover, Yogita P. Patil, Alberto Gabizón	125
17	Pregnancy Outcome Following In Utero Exposure to Lithium: A Prospective, Comparative, Observational Study 2014 ·American Journal of Psychiatry ·Orna Diav‐Citrin, Svetlana Shechtman, Esther Tahover, (unknown), Judy Arnon, (unknown), (unknown), Adrienne Einarson, Asher Ornoy	88
18	[Update: adjuvant trastuzumab in HER2 positive breast cancer]. 2012 ·PubMed ·Esther Tahover, Amir Sonnenblick, Tamar Peretz, Daniela Katz	1
19	Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients 2012 ·Medical Oncology ·Esther Tahover, Beatrice Uziely, Azzam Salah, Mark Temper, Tamar Peretz, Ayala Hubert	37
20	P-0214 Hypertension as A Predictive Biomarker in Bevacizumab 2012 ·Annals of Oncology ·Esther Tahover, Beatrice Uziely, Mark Temper, Azzam Salah, Tamar Peretz, Ayala Hubert	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact